---
title: HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after
  hematopoietic stem cell transplantation
date: '2024-04-29'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38683966/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240430181459&v=2.18.0.post9+e462414
source: Blood
description: Relapse is the leading cause of death after allogeneic hematopoietic
  stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer
  to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor
  histocompatibility (H) antigens may provide a potent selective anti-leukemic effect
  post-HCT. We conducted a phase I clinical trial employing a novel TCR-T product
  targeting the minor H antigen HA-1 to treat or consolidate treatment of persistent
  or ...
disable_comments: true
---
Relapse is the leading cause of death after allogeneic hematopoietic stem cell transplantation (HCT) for leukemia. T cells engineered by gene transfer to express T cell receptors (TCR; TCR-T) specific for hematopoietic-restricted minor histocompatibility (H) antigens may provide a potent selective anti-leukemic effect post-HCT. We conducted a phase I clinical trial employing a novel TCR-T product targeting the minor H antigen HA-1 to treat or consolidate treatment of persistent or ...